Clinical Trials Logo

Nervous System Diseases clinical trials

View clinical trials related to Nervous System Diseases.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06450717 Recruiting - Clinical trials for Neurological Diseases or Conditions

IMPLEMENTATION OF A PILOT TELEREHABILITATION NETWORK IN PEDIATRIC PATIENTS WITH COMPLEX NEURODSABILITIES MedeaNeuroTelerehab-Net (MENTE.NET STUDY)

Start date: December 28, 2022
Phase: N/A
Study type: Interventional

This pilot study aims at networking the experience gained in neurorehabilitation of developmental neurodisabilities from the 3 poles of IRCCS Medea (Brindisi, Bosisio Parini, and Conegliano) to assess the feasibility of performing home-based telerehabilitation on cognitive and motor aspects through the Khymeia Virtual Reality Rehabilitation System (VRRS) platform.

NCT ID: NCT06442982 Recruiting - Clinical trials for Gait Disorders, Neurologic

Analyzing Gait Pattern Using Insole-type Gait Analyzer in Patient With Gait Disturbance

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the usefulness of information from insole-type gait analyzer in adults with subjective gait and balance disorders. The main questions it aims to answer are: How useful is an insole-type gait analyzer for collecting gait data from patients with gait disturbances? Researchers will explore the usefulness of collected data and does not establish a control group. Participants will: Participants will conduct survey and perform the Timed up and go test wearing an insole-type gait analyzer.

NCT ID: NCT06418698 Recruiting - Stroke Clinical Trials

The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy

CAIS-MT
Start date: March 28, 2024
Phase:
Study type: Observational [Patient Registry]

CAIS-MT is a single-center, prospective cohort study, to evaluate the correlation between outcomes of endovascular treatment(EVT) and intracranial artery calcification(IAC) in patients with acute ischemic stroke due to large or medium vessel occlusion.

NCT ID: NCT06410755 Recruiting - Clinical trials for Gait Disorders, Neurologic

Home-based Gait Rehabilitation Service Using Instrumented Insole

Start date: March 12, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn if monitoring and providing feedback on the performance of a home-based exercise program using an insole gait analyzer to treat participants who have gait disorder. The investigators also learn about the satisfaction level of this insole type gait analysis system. The main questions it aims to to answer are: - What effect does providing monitoring and feedback using an insole-type gait analyzer have on walking patterns? - How satisfied are the experimental group participants with the use of the insole gait analyzer? Researchers will compare the experimental group that receives the insole-type gait analyzer with the control group that does not receive it. Participants will: - Receive an insole-type gait analyzer and receive training in a home-based exercise program. - During the 6-week program, participants will wear an insole-type gait analyzer and perform a home-based exercise program. - The investigators will conduct a satisfaction survey after 6 weeks.

NCT ID: NCT06407154 Recruiting - Stroke Clinical Trials

Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures: an Observational Study, 2nd Wave

CLIMATE-II
Start date: May 21, 2024
Phase:
Study type: Observational

The CLIMATE-II Observational Study examines to what extent chronically ill patients experience adverse health effects because of heat and whether the patients' specific health behavior, somatosensory amplification, risk and benefit perception, self-efficacy, health literacy, degree of urbanisation of the patients' administration district and characteristics of the patients' neighborhood are associated with these effects.

NCT ID: NCT06406127 Recruiting - Breast Cancer Clinical Trials

Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

92 female cancer patients, aged from 18 to 75 years old (with a first diagnosis of breast cancer) who will receive Paclitaxel-based chemotherapy (12 weeks) as first line therapy, will be enrolled in the study and will be randomly assigned to either: - Group I: will receive the chemotherapy protocol or - Group II: will receive the chemotherapy protocol plus 600 mg daily dose of Alpha Lipoic Acid for 14 weeks (one week before the start of paclitaxel and continue till one week after the end of paclitaxel). * Blood samples will be withdrawn 2 times (week 1 and week 12) to measure the following: (Stored in -80 C till the end of the study) - Tumor Necrotizing Factor- alpha (TNF-α) by ELISA. - Brain-Derived Neurotrophic Factor (BDNF) by ELISA. * All patients will be subjected to 6 tests/questionnaires (week 1 - week 12 - week 24) to predict the functionality of the brain: - Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) version 3 - Mini-Cog Test - Mini Mental State Examination (MMSE) - Controlled Oral Word Association Test (COWAT) - Hopkins Verbal Learning Test (HVLT) - Trail Making Test (TMT)

NCT ID: NCT06393465 Recruiting - Clinical trials for Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

Start date: May 19, 2024
Phase:
Study type: Observational

This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records

NCT ID: NCT06343558 Recruiting - Healthy Clinical Trials

Gait and Balance Impairment in Rare and Very Rare Neurological Diseases

GALVANISE
Start date: May 30, 2023
Phase:
Study type: Observational [Patient Registry]

Rare and very rare neurological diseases primarily or exclusively affect the nervous system with a prevalence of < 5 out of 10'000 and 100'000 people, respectively. Besides these, there are undiagnosed neurological diseases: neurological conditions without a diagnosis after completing a full diagnostic examination. Rare, very rare, and undiagnosed neurological diseases are complicated and progressive and often cause variegated motor signs, impairments, and syndromes. Balance and gait are frequently affected in these conditions, already at the clinical examination. These balance and gait impairments limit activities and cause an increased risk of falling. Falls can eventually result in injuries, even severe. There are only a few studies about these diseases, likely because of their rarity. Hence, the clinical presentation and the course of rare and very rare diseases are poorly known or even unknown. Essential information for these conditions' diagnosis, prognosis, treatment and rehabilitation is missing. MaNeNeND is an observational study underway at the Fondazione IRCCS Istituto Neurologico "Carlo Besta" (Milano) aimed at detailing the clinical and biological features of very rare and undiagnosed neurological diseases. Research questions: 1. Do patients with rare (Ra), very rare (V) and undiagnosed (U) neurological diseases suffer a balance and gait impairment? 2. Is there a correlation between the clinical and instrumental severity of the balance and gait impairment in RaVU neurological diseases? 3. Are instrumental measures more sensitive in detecting balance and gait impairments in patients affected by a RaVU neurological disease than the clinical measures? 4. Do the balance and gait impairments in RaVU neurological diseases worsen in time? The current project aims at diagnosing, quantifying and detailing the balance and gait impairment in rare, very rare and undiagnosed neurological diseases. To this aim, questionnaires, clinical scales and instrumental tests will be administered to these patients to collect a wide range of balance and gait measures. These measures will also integrate those collected with MaNeNeND to provide a more detailed description of patients with rare, very rare and diagnosed neurological diseases. Participants will complete two questionnaires: the Dizziness Handicap Inventory - short form (DHI-sf, an ordinal score of self-perceived balance) and the Modified Fatigue Impact Scale (MFIS, an ordinal score of self-perceived fatigue). Moreover, a clinician will administer the Mini Balance Evaluation Systems Test (Mini-BESTest, an ordinal score of balance), the 10 m walking test (for measuring the gait speed and other gait parameters) and the Timed Up and Go test (an instrumental measure of mobility and balance). Walking and the Timed Up and Go tests will be recorded with a trunk-worn inertial measurement unit. Finally, participants will be asked to complete an instrumental upright stance and gait assessment, the first consisting of standing on posturographic plates and the second of walking on a treadmill equipped with force sensors. When walking on the treadmill, an optoelectronic system will also record the position in time of limbs and trunk. The quantification of the severity of the balance and gait impairment of the patients suffering a rare, very rare or undiagnosed neurological disease will highlight these persons' therapeutic and rehabilitative needs. Comparing the balance and gait impairment of rare, very rare and undiagnosed diseases with those of multiple sclerosis, Parkinson's disease and peripheral neuropathy will highlight if the formers' balance and gait impairment has unique characteristics that could help ease the diagnosis of these uncommon conditions. The longitudinal measurements on rare, very rare and undiagnosed diseases will be paramount to identifying prognostic factors. In addition, the data collected in the current study will be crucial for future studies, for example, for estimating the sample size in clinical trials.

NCT ID: NCT06329453 Recruiting - Multiple Sclerosis Clinical Trials

Intestinal Immunity in Neurologic Disease

Start date: August 2, 2022
Phase:
Study type: Observational

The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.

NCT ID: NCT06314776 Recruiting - Cerebral Palsy Clinical Trials

Whole-Body Vibration Therapy in the Gait of Children With Cerebral Palsy

Start date: March 11, 2024
Phase: N/A
Study type: Interventional

Observation of the effect of vibration therapy on the gait of children with cerebral palsy and the analysis of their functional evolution